Torrent Pharmaceuticals revenue and financials
₹4,716.20Change from previous close: −1.17%Absolute change: −₹55.80
In the fiscal year ended March 2026, Torrent Pharmaceuticals reported revenue of ₹137.53B (+21.52% year over year). Net income was ₹21.63B, a net margin of 15.7%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +21.52%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +13.19%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 15.7%
- FY to Mar 2025: 16.9%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Operating cash flow | 30,227 | 25,851 | 32,661 | 23,681 | — |
| Depreciation and amortization | 11,189 | 7,949 | 7,953 | 7,020 | — |
| Capital expenditure | -6,774 | -6,119 | -4,328 | -5,739 | — |
| Investing cash flow | -127,124 | -5,401 | -1,679 | -24,153 | — |
| Financing cash flow | 101,506 | -22,980 | -27,796 | 774 | — |
| Dividends paid | -12,889 | -10,830 | -10,153 | -8,630 | — |
| Debt issued | 125,941 | 0.0 | 0.0 | 13,950 | — |
| Debt repaid | -6,721 | -9,255 | -13,694 | -9,718 | — |
| Effect of exchange rates | 828 | -87.3 | 80.7 | 211 | — |
| Net change in cash | 4,609 | -2,529 | 3,185 | 302 | — |
| Free cash flow | 23,453 | 19,732 | 28,333 | 17,942 | — |